Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation

Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation is a phase 2, randomised interventional study registered as NCT06634056 by University Health Network, Toronto, with a registry enrolment figure of 150 participants, started 2026-06-15 and due to reach its primary completion in 2031-11-30. Interventions recorded: Pentoxifylline; Placebo; α-Tocopherol. Conditions listed: Non-Small Cell Lung Cancer; Radiation Induced Lung Injury (RILI). Primary outcome: Change in risk of Lung Injury. Lung eligibility wording from the registry: "* Histologically confirmed diagnosis of stage III NSCLC, planned for treatment with concurrent chemoradiation and consolidation immune checkpoint inhibitor as per standard of care with no medical contraindications to therapy". Sites: Canada. No results are recorded here; the registry entry is the source.